• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.

作者信息

Donahue Sean P, Recchia Franco, Sternberg Paul

出版信息

Am J Ophthalmol. 2010 Aug;150(2):287; author reply 287. doi: 10.1016/j.ajo.2010.04.006.

DOI:10.1016/j.ajo.2010.04.006
PMID:20670740
Abstract
摘要

相似文献

1
Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.贝伐单抗与雷珠单抗治疗年龄相关性黄斑变性：一项前瞻性双盲随机临床试验的早期结果
Am J Ophthalmol. 2010 Aug;150(2):287; author reply 287. doi: 10.1016/j.ajo.2010.04.006.
2
Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.贝伐单抗与雷珠单抗治疗年龄相关性黄斑变性：一项前瞻性双盲随机临床试验的早期结果
Am J Ophthalmol. 2009 Dec;148(6):875-82.e1. doi: 10.1016/j.ajo.2009.07.009. Epub 2009 Oct 2.
3
Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions.贝伐单抗与雷珠单抗治疗年龄相关性黄斑变性的随机研究：不恰当的结论。
Am J Ophthalmol. 2010 May;149(5):867; author reply 867. doi: 10.1016/j.ajo.2009.12.039.
4
Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.雷珠单抗灵活给药方案治疗新生血管性年龄相关性黄斑变性的安全性和有效性：SUSTAIN 研究。
Ophthalmology. 2011 Apr;118(4):663-71. doi: 10.1016/j.ophtha.2010.12.019.
5
Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.基于新生血管性年龄相关性黄斑变性初始稳定后视力变化的抗血管内皮生长因子治疗的再治疗：3 年随访结果。
Retina. 2012 Sep;32(8):1471-9. doi: 10.1097/IAE.0b013e318236e805.
6
Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.局部应用溴芬酸作为辅助治疗与玻璃体内雷珠单抗联合治疗渗出型年龄相关性黄斑变性。
Retina. 2012 Oct;32(9):1804-10. doi: 10.1097/IAE.0b013e31825be87f.
7
Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.超剂量抗血管内皮生长因子（SAVE）试验：玻璃体内注射 2.0mg 雷珠单抗治疗难治性新生血管性黄斑变性 - 主要终点。
Ophthalmology. 2013 Feb;120(2):349-54. doi: 10.1016/j.ophtha.2012.08.008. Epub 2012 Nov 3.
8
Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study.固定间隔与 OCT 引导的可变剂量玻璃体内注射贝伐单抗治疗新生血管性年龄相关性黄斑变性：一项 12 个月的随机前瞻性研究。
Am J Ophthalmol. 2012 Mar;153(3):481-489.e1. doi: 10.1016/j.ajo.2011.08.018. Epub 2011 Oct 19.
9
Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.玻璃体内注射贝伐单抗与雷珠单抗治疗新生血管性年龄相关性黄斑变性的短期疗效。
Retina. 2009 Oct;29(9):1235-41. doi: 10.1097/IAE.0b013e3181b20eed.
10
Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.玻璃体内注射贝伐单抗与玻璃体内注射贝伐单抗联合曲安奈德治疗新生血管性年龄相关性黄斑变性：一项随机临床试验的 6 个月结果。
Retina. 2011 Oct;31(9):1819-26. doi: 10.1097/IAE.0b013e31820d58f2.

引用本文的文献

1
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.抗血管内皮生长因子用于治疗新生血管性年龄相关性黄斑变性。
Cochrane Database Syst Rev. 2019 Mar 4;3(3):CD005139. doi: 10.1002/14651858.CD005139.pub4.
2
Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.玻璃体内注射贝伐单抗与雷珠单抗治疗年龄相关性黄斑变性后的全身不良事件：一项荟萃分析。
PLoS One. 2014 Oct 16;9(10):e109744. doi: 10.1371/journal.pone.0109744. eCollection 2014.
3
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
抗血管内皮生长因子用于治疗新生血管性年龄相关性黄斑变性。
Cochrane Database Syst Rev. 2014 Aug 29;8(8):CD005139. doi: 10.1002/14651858.CD005139.pub3.
4
LiGluR restores visual responses in rodent models of inherited blindness.LiGluR 可恢复遗传性失明啮齿动物模型的视觉反应。
Mol Ther. 2011 Jul;19(7):1212-9. doi: 10.1038/mt.2011.103. Epub 2011 May 24.
5
Targeting non-malignant disorders with tyrosine kinase inhibitors.用酪氨酸激酶抑制剂靶向非恶性疾病。
Nat Rev Drug Discov. 2010 Dec;9(12):956-70. doi: 10.1038/nrd3297.